Michael Chen
Chief Scientific Officer Seaport Therapeutics
Seminars
Thursday 17th September 2026
Transforming Anxiety & Mood Disorder Therapeutics: Advancing GlyphAgo™ (SPT 320), SPT 300, & SPT 348 in Next Generation Neuropsychiatric Care
1:00 pm
- Advancing clinically validated mechanisms such as allopregnanolone, agomelatine and non hallucinogenic neuroplastogens through the Glyph™ platform, which overcomes limitations like low oral bioavailability, hepatotoxicity and poor PK profiles
- Enabling safer, more predictable anxiolytic and antidepressant activity by rerouting drug absorption through intestinal lymphatics, reducing liver exposure and supporting therapeutic plasma levels at lower doses, as demonstrated in early studies of GlyphAgo™ (SPT 320)
- Positioning SPT 300, an oral allopregnanolone prodrug, as a potential new option for major depressive disorder by unlocking a previously IV only mechanism through improved systemic exposure and tolerability
- Expanding treatment reach with SPT 348, a next generation non hallucinogenic neuroplastogen aimed at mood and neuropsychiatric disorders, designed to improve pharmacokinetics and tolerability while maintaining circuit modulating effects
Thursday 17th September 2026
Panel Discussion: Understanding Anxiety: Key Biology & Clinical Features, Sleep Cross-section & Comorbidities
1:30 pm
- Exploring the core brain and stress response mechanisms that drive anxiety across different disorders
- Understanding how specific sleep problems: trouble falling asleep, staying asleep, early waking, or poor quality sleep can worsen anxiety and shape symptom patterns
- Recognizing how common comorbidities like depression, anhedonia and PTSD interact with anxiety and influence clinical presentation
- Identifying practical tools and measures clinicians and researchers can use to build a clearer picture of anxiety across diverse patient groups
Tuesday 15th September 2026
Panel Discussion: Evaluating Unmet Needs in Sleep: Navigating EEG Utility & Limitations Across Complex Sleep Architecture
3:15 pm
- Defining which facets of sleep (onset, maintenance, early awakening, quality, or EEG specific signals) truly matter as clinical biomarkers
- Understanding the practical and scientific limits of EEG in psychiatric sleep research: specificity, invasiveness, and placebo susceptibility
- How sponsors (orexin programs, sleep promoting or circadian targeting drugs) and EEG tech vendors interpret sleep architecture in different disease contexts
- Identifying core unmet needs in insomnia and sleep dysregulation across mood and psychiatric disorders, and what measurement innovation is required
